Jinghua Pharmaceutical Group Co., Ltd. (SHE:002349)
7.16
-0.05 (-0.69%)
May 20, 2026, 1:35 PM CST
SHE:002349 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,462 | 1,446 | 1,388 | 1,496 | 1,550 | 1,336 |
Other Revenue | 13.85 | 13.85 | 13.63 | 15.41 | 22.58 | 21.41 |
| 1,476 | 1,460 | 1,402 | 1,512 | 1,573 | 1,358 | |
Revenue Growth (YoY) | 5.56% | 4.13% | -7.25% | -3.90% | 15.85% | 5.97% |
Cost of Revenue | 707.44 | 713.15 | 719.73 | 781.18 | 847.06 | 739.21 |
Gross Profit | 768.74 | 746.8 | 682.36 | 730.58 | 726 | 618.66 |
Selling, General & Admin | 398.23 | 394.33 | 366.72 | 346.78 | 401.01 | 352.64 |
Research & Development | 68.78 | 64.99 | 61.79 | 64.62 | 86.98 | 74.76 |
Other Operating Expenses | 20.96 | 20.04 | 17.48 | 17.77 | 22.39 | 20.17 |
Operating Expenses | 489.76 | 479.82 | 449.36 | 431.89 | 514.64 | 462.16 |
Operating Income | 278.98 | 266.98 | 233 | 298.69 | 211.36 | 156.51 |
Interest Expense | -0.46 | -0.57 | -1.34 | -2.57 | -6.79 | -12.94 |
Interest & Investment Income | 30.61 | 30.3 | 48.38 | 23.87 | 39.71 | 14.16 |
Currency Exchange Gain (Loss) | -2.55 | -2.55 | 2.34 | 2.35 | 6.86 | -1.48 |
Other Non Operating Income (Expenses) | -2.3 | -0.21 | -0.3 | 0.43 | -1.24 | 1.45 |
EBT Excluding Unusual Items | 304.29 | 293.96 | 282.09 | 322.76 | 249.9 | 157.7 |
Gain (Loss) on Sale of Investments | 4.71 | 4.17 | 3.82 | 6.83 | 4.99 | 31.44 |
Gain (Loss) on Sale of Assets | -0.03 | -0.01 | -0.2 | -0.09 | -0.06 | -0.58 |
Asset Writedown | -1 | -1.14 | -2.13 | -4.52 | -16.96 | -16.7 |
Other Unusual Items | 6.62 | 6.62 | 9.75 | 4.71 | 12.34 | 7.03 |
Pretax Income | 314.59 | 303.61 | 293.32 | 329.7 | 250.21 | 178.89 |
Income Tax Expense | 42.52 | 41.77 | 45.85 | 53.23 | 37.92 | 38.93 |
Earnings From Continuing Operations | 272.07 | 261.84 | 247.47 | 276.47 | 212.29 | 139.96 |
Minority Interest in Earnings | -49.13 | -42.55 | -34.81 | -28.77 | -0.06 | 20.74 |
Net Income | 222.94 | 219.28 | 212.65 | 247.7 | 212.23 | 160.7 |
Net Income to Common | 222.94 | 219.28 | 212.65 | 247.7 | 212.23 | 160.7 |
Net Income Growth | 9.40% | 3.12% | -14.15% | 16.71% | 32.06% | 44.79% |
Shares Outstanding (Basic) | 819 | 819 | 814 | 814 | 814 | 814 |
Shares Outstanding (Diluted) | 820 | 819 | 814 | 814 | 814 | 814 |
Shares Change (YoY) | 0.66% | 0.58% | -0.01% | 0.02% | -0.00% | -0.03% |
EPS (Basic) | 0.27 | 0.27 | 0.26 | 0.30 | 0.26 | 0.20 |
EPS (Diluted) | 0.27 | 0.27 | 0.26 | 0.30 | 0.26 | 0.20 |
EPS Growth | 8.68% | 2.53% | -14.13% | 16.69% | 32.07% | 44.83% |
Free Cash Flow | 293.79 | 320.54 | 280.1 | 262.93 | 296.8 | 225.02 |
Free Cash Flow Per Share | 0.36 | 0.39 | 0.34 | 0.32 | 0.36 | 0.28 |
Dividend Per Share | 0.090 | 0.090 | 0.080 | 0.092 | 0.080 | 0.060 |
Dividend Growth | 12.50% | 12.50% | -13.04% | 15.00% | 33.33% | 46.34% |
Gross Margin | 52.08% | 51.15% | 48.67% | 48.33% | 46.15% | 45.56% |
Operating Margin | 18.90% | 18.29% | 16.62% | 19.76% | 13.44% | 11.53% |
Profit Margin | 15.10% | 15.02% | 15.17% | 16.38% | 13.49% | 11.83% |
Free Cash Flow Margin | 19.90% | 21.96% | 19.98% | 17.39% | 18.87% | 16.57% |
EBITDA | 359.49 | 346.42 | 308.14 | 382.89 | 319.43 | 257.8 |
EBITDA Margin | 24.35% | 23.73% | 21.98% | 25.33% | 20.31% | 18.99% |
D&A For EBITDA | 80.51 | 79.43 | 75.14 | 84.21 | 108.07 | 101.29 |
EBIT | 278.98 | 266.98 | 233 | 298.69 | 211.36 | 156.51 |
EBIT Margin | 18.90% | 18.29% | 16.62% | 19.76% | 13.44% | 11.53% |
Effective Tax Rate | 13.52% | 13.76% | 15.63% | 16.14% | 15.16% | 21.76% |
Revenue as Reported | 1,476 | 1,460 | 1,402 | 1,512 | 1,573 | 1,358 |
Advertising Expenses | - | 9.31 | 13.69 | 13.65 | 7.27 | 11.6 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.